Received Jan 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | — | — |
MENQUADFI back in 2019 to receive a second dose 6 years after the first one, and a third dose 6 months after the second dose, with no reported adverse event; Initial information received on 22-Jan-2026 regarding an unsolicited valid non-serious case received from a other health professional. This case involves an unknown age /gender patient who experienced MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE [MENQUADFI] back in 2019 to receive a second dose 6 years after the first one, and a third dose 6 months after the second dose, with no reported adverse event The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date in 2019, the patient received a dose 1 of suspect MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE, Solution for injection and receive a second dose 6 years after the first one, and a third dose 6 months after the second dose, with no reported adverse event (extra dose administered) (dose, strength, route, lot and expiry: unknown for all dose) for immunization. Information on batch number and expiry date corresponding to the one at time of event occurrence was requested. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.